July, 2024
July 2024
Piotr Wysocki: Adjuvant endocrine treatment in single and unemployed young breast cancer patients
Jun 29, 2024, 05:21

Piotr Wysocki: Adjuvant endocrine treatment in single and unemployed young breast cancer patients

Piotr Wysocki recently posted on LinkedIn:

“The study by Julie A. Schmidt et al. published online in the Journal of Clinical Oncology evaluated the influence of social characteristics such as marital status and socioeconomic position (education, employment, and income) on the adherence to adjuvant endocrine therapy (AET) among premenopausal women with estrogen receptor-positive breast cancer diagnosed in Denmark between 2002 and 2011.

The researchers identified adherence patterns using national registry data over five years post-diagnosis. The results showed three adherence trajectories among 4,353 patients: high adherence (57%), slow decline (36%), and rapid decline (6.9%). Key findings include:

1. Women living alone had higher odds of experiencing a slow or rapid decline in adherence than those cohabiting.

2. Unemployed women also showed lower adherence rates than their employed counterparts.

3. The study suggests that non-cohabiting and unemployed women are at higher risk of early discontinuation of AET.

The conclusion drawn is that women who live alone or are unemployed face challenges in maintaining AET adherence and could benefit from targeted support programs to improve their treatment outcomes.”

Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Breast Cancer


Authors: Julie A. Schmidt, Kirsten M. Woolpert, Cathrine F. Hjorth, Dóra K. Farkas, Bent Ejlertsen andDeirdre Cronin-Fenton.

Source: Piotr Wysocki/LinkedIn

Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.

His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.

Read other posts by Piotr Wysocki published on OncoDaily.